Literature DB >> 21209243

Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study.

Alette M Wessels1, Robert R Bies, Bruce G Pollock, Lon S Schneider, Jeffrey A Lieberman, Scott Stroup, Claire H Li, Kim Coley, Margaret M Kirshner, Stephen R Marder.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21209243     DOI： 10.1177/0091270010387604

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN： 0091-2700            Impact factor:   3.126


× No keyword cloud information.
  8 in total

1.  Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice.

Authors:  Vidya Perera; Robert R Bies; Gary Mo; Michael J Dolton; Vaughan J Carr; Andrew J McLachlan; Richard O Day; Thomas M Polasek; Alan Forrest
Journal:  Br J Clin Pharmacol       Date:  2014-10       Impact factor: 4.335

Review 2.  Perphenazine for schizophrenia.

Authors:  Benno Hartung; Stephanie Sampson; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2015-03-06

3.  Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.

Authors:  Hitoshi Sakurai; Robert R Bies; Scott T Stroup; Richard S E Keefe; Tarek K Rajji; Takefumi Suzuki; David C Mamo; Bruce G Pollock; Koichiro Watanabe; Masaru Mimura; Hiroyuki Uchida
Journal:  Schizophr Bull       Date:  2012-01-30       Impact factor: 9.306

4.  Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study.

Authors:  Takefumi Suzuki; Ariel Graff-Guerrero; Hiroyuki Uchida; Gary Remington; Fernando Caravaggio; Carol Borlido; Bruce Pollock; Benoit Mulsant; Vincenzo Deluca; Zahinoor Ismail; David Mamo
Journal:  Psychopharmacology (Berl)       Date:  2013-02-17       Impact factor: 4.530

5.  Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building.

Authors:  Eric A Sherer; Mark E Sale; Bruce G Pollock; Chandra P Belani; Merrill J Egorin; Percy S Ivy; Jeffrey A Lieberman; Stephen B Manuck; Stephen R Marder; Matthew F Muldoon; Howard I Scher; David B Solit; Robert R Bies
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-07-06       Impact factor: 2.745

Review 6.  Ziprasidone versus other atypical antipsychotics for schizophrenia.

Authors:  Katja Komossa; Christine Rummel-Kluge; Heike Hunger; Sandra Schwarz; Paranthaman Seth S Bhoopathi; Werner Kissling; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

7.  Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.

Authors:  Kazunari Yoshida; Robert R Bies; Takefumi Suzuki; Gary Remington; Bruce G Pollock; Yuya Mizuno; Masaru Mimura; Hiroyuki Uchida
Journal:  Schizophr Res       Date:  2014-02-01       Impact factor: 4.939

8.  Genetic variation in CYP3A43 explains racial difference in olanzapine clearance.

Authors:  K L Bigos; R R Bies; B G Pollock; J J Lowy; F Zhang; D R Weinberger
Journal:  Mol Psychiatry       Date:  2011-04-26       Impact factor: 15.992
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.